Equity Details
Price & Market Data
Price: $5.07
Daily Change: -$0.08 / 1.58%
Daily Range: $4.72 - $5.20
Market Cap: $58,902,980
Daily Volume: 38,528
Performance Metrics
1 Week: 13.04%
1 Month: 73.04%
3 Months: 88.48%
6 Months: 19.29%
1 Year: 296.1%
YTD: 29.01%
About Lixte Biotechnology Holdings, Inc. (LIXT)
Data on Lixte Biotechnology Holdings, Inc. (LIXT). Price: 5.07, daily change: -$0.08 / 1.58%. Market cap: 58,902,980. Performance YTD and 1-year.
Company Details
Employees: 3
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.